Atrial fibrillation
Conditions
Interventions
Intervention:Dapagliflozin 10mg/day
Control:No intervention
Sponsors
Affiliated Drum Tower Hospital, Nanjing University School of Medicine
Eligibility
Sex/Gender
Male
Age
18 Years to 80 Years
Inclusion criteria
Inclusion criteria: 1. Patients with dual-chamber permanent pacemaker with advanced atrial fibrillation detection algorithms and paroxysmal atrial fibrillation and a device burden between 1 and 50% during the last month were recruited.
Exclusion criteria
Exclusion criteria: 1. Patients with permanent pacemaker without advanced atrial fibrillation detection algorithms; 2. Persistent atrial fibrillation; 3. Heart failure with NYHA function III-IV; 4. Severe valvular disease or have prosthetic valve; 5. Previous treatment with AF ablation or plan to receive ablation within 6 months; 6. Receiving cardiac surgery in the last 3 months, or plan to receive within 6 months; 7. Type 1 DM, or other clinically uncontrolled endocrine disease; 8. Severe kidney dysfunction eGFR3 upper normal limit, or bilirubin > 2 upper normal limit); 10. Acute cardiovascular event [e.g., stroke, TIA, acute coronary syndrome (ACS), revascularization ] < 2 months prior to baseline study; 11. Chronic cystitis and/or recurrent genitourinary tract infections (3 or more in the last year); 12. Previous treatment with any SGLT2 inhibitor in the last month; 13. Previous DKA, Diabetic coma, or frequent Hypoglycemic episode; 14. Malnutrition or BMI <18.5 kg/m2; 15. Remarkable hemorrhagic tendency, Hematological diseases, or myelosuppression; 16. History of any malignancy within 5 years; 17. Pregnant women, lactation, or plan to pregnant within 1 year; 18. Acute or severe system infection; 19. Subject for another clinical trial; 20. Any known drug or alcohol dependence, difficulty understanding the test protocol, inability or unwillingness to follow up with the test protocol; 21. Patients with moderate to severe cognitive impairment and no permanent guardian; 22. Patients considered unsuitable for the study by the investigator.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Burden of atrial fibrillation; | — |
Secondary
| Measure | Time frame |
|---|---|
| Life quality;Frequency of atrial fibrillation; | — |
Countries
China
Contacts
Public ContactWei Xu
Affiliated Drum Tower Hospital, Nanjing University School of Medicine
Outcome results
None listed